On March 29, 2023 ProQR will host a virtual R&D event to showcase its proprietary Axiomer RNA-editing technology platform. ProQR will also announce initial pipeline targets for internal development.
LEIDEN, the Netherlands, Jan. 08, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), today announced that it has entered into a research collaboration agreement with Galapagos N.V. (Euronext & NASDAQ:GLPG).
Agreement provides ProQR with initial payment of €12.5M and up to €135M in further payments, as well as potential additional earn outs based on commercial sales in the US and EU
Divestment of sepofarsen and ultevursen supports ProQR’s strategic focus on the Axiomer®&
Access based on positive interim analysis of clinical data as well as preclinical data to date PRIME designation provides a pathway for frequent and early interactions with the EMA aimed at supporting accelerated evaluation and approval